clinical trial · NCT04932941
MP1032 Treatment in Patients With Moderate to Severe COVID-19
COVID-19MP1032Placebo
brief summary
The purpose of this study is to evaluate the efficacy and safety of MP1032 with standard of care (SoC) verses placebo with SoC in hospitalized adults participants with moderate to severe coronavirus disease 2019 (COVID-19).
started
Oct 19, 2021
primary completion
Jul 28, 2022
completion
Sep 5, 2022
last updated
Jun 29, 2023
official title
A Randomized, Double-blind, Placebo-controlled, Multicenter, Proof-of-concept, Phase IIA Study of MP1032 Plus Standard of Care vs Standard of Care in the Treatment of Hospitalized Participants With Moderate to Severe COVID-19
sourced from ClinicalTrials.gov · pharmadog mirrors structured fields, not the full protocol